© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
June 17, 2020
With a “new normal” level of care going forward post coronavirus disease 2019 (COVID-19), the key will be to invest in high-value services while deterring a resurgence of low-value care.
December 11, 2019
This review presents a set of evidence-based outcome measures for oncology alternative payment models, drawing on evidence from existing and proposed quality measures.
October 08, 2019
Health plans restrict orphan drug coverage less often than nonorphan drug coverage. However, the frequency of restrictions varies considerably across plans.
November 13, 2018
New value frameworks should incorporate real-world evidence that reflects patient treatment behavior, adherence to medication, and equity concerns arising from disparities in care.
September 12, 2016
The authors examine the largest 20 US commercial payers’ coverage policies and identify variation in how interventions are covered and the evidence reviewed in them.
August 16, 2016
The authors review empirical evaluations of drug exclusion policies to examine their impact on patients and on healthcare costs.
September 15, 2015
Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.
February 27, 2015
This study's findings showed that diabetes care remained suboptimal among many patients with multiple chronic conditions and that patient outcomes varied by multimorbidity profile.
June 19, 2014
This study examines whether patients treated with specialty pharmaceuticals have improved outcomes compared with patients treated with conventional therapies, and evaluates costs associated with these treatments.
April 07, 2010
Building negative incentives into value-based insurance design programs to discourage use of low-value care will involve a number of challenges.